Associate Vice President - HEOR - Oncology

At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to our communities through philanthropy and volunteerism. We give our best effort to our work, and we put people first. We’re looking for people who are determined to make life better for people around the world.

Organization Overview  ​

At Lilly, we serve an extraordinary purpose. We make a difference for people around the globe by discovering, developing and delivering medicines that help them live longer, healthier, more active lives. Not only do we deliver breakthrough medications, but you also can count on us to develop creative solutions to support communities through philanthropy and volunteerism. 

Role Overview

This role is the accountable leader for global Health Economics and Outcomes Research (HEOR) strategy and execution within the Oncology Business Unit. The M4 owns the HEOR program end-to-end across all OBU assets, partnering with tumor teams, clinical development, market access, commercial, and payer-facing functions to ensure a rigorous, strategically aligned evidence base that supports the clinical and economic value of Lilly oncology medicines. This is a leadership role where the Global Medical Affairs HEOR Lead is expected to make decisions, anticipate risks, drive team performance, and deliver results with urgency.

Leadership Expectations

The M4 is expected to demonstrate the following leadership behaviors as a baseline requirement of the role:

• Scientific & Methodological Command: Maintain comprehensive, continuously updated mastery of HEOR methodologies — including patient-reported outcomes (PROs), real-world evidence (RWE) design, cost-effectiveness modeling, burden of illness research, and comparative effectiveness — as applied to oncology. The M4 must be the definitive HEOR authority within the OBU and credible to payers, HTA bodies, and scientific peers.
• Program Ownership: Own the HEOR evidence portfolio as a business priority. Anticipate gaps in the evidence base, identify issues before they surface, and drive proactive solutions across tumor teams.
• Accountability & Decision-Making: Be accountable for program outcomes by making decisions and clearly identifying HEOR priorities across a complex, multi-asset portfolio.
• Strategic Thinking: Connect scientific, economic, and payer landscape insights to shape the HEOR strategy. Lead a strong HEOR point of view with cross-functional and affiliate leaders.
• Urgency & Delivery: Operate with a bias toward action. Drive timelines, remove obstacles, and deliver HEOR evidence commitments aligned to asset milestones and payer access needs.
• Cross-Functional Partnership: Effectively partner with tumor leads, GPLs, clinical development, market access, commercial, and affiliate leaders to integrate HEOR evidence into a single, cohesive asset strategy.
• People Leadership: Lead, coach, and develop the HEOR team, setting clear expectations and holding team members accountable for performance, impact, and professional growth.
• Team Culture: Create a collaborative, high-performance, inclusive team culture where candid feedback, coaching, and peer learning are the norm.

HEOR Strategy & Execution

• Own the global HEOR strategy across the OBU portfolio, from early pipeline through lifecycle management. Ensure evidence generation plans are prospectively integrated into clinical development and medical affairs planning while appropriately prioritizing asset risk and OBU strategy.
• Develop and maintain a portfolio-level HEOR evidence roadmap that identifies data gaps, prioritizes studies by asset and indication, and aligns to value demonstration milestones.
• Facilitate the design, execution, and oversight of HEOR studies including PRO endpoint strategy, health utility studies, indirect treatment comparisons (ITCs), cost-effectiveness models, real-world evidence studies, and burden of illness analyses.
• Own the integrated PRO and patient experience strategy for OBU assets — including endpoint selection, instrument validation, data collection, and communication of PRO findings in publications and HTA submissions.
• Oversee real-world evidence strategy and execution in partnership